Two Sigma Securities’s Moleculin Biotech MBRX Stock Holding History

Two Sigma Securities’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2	Closed	-$7.59K	–	3261
2023 Q2	$7.59K	Hold	2	–	–	﹤0.01%	2629
2023 Q1	$13K	Buy	+2	New	+$17.5K	﹤0.01%	2423
2022 Q1	–	Sell	-3	Closed	-$41K	–	2349
2021 Q4	$41K	Buy	+3	New	+$53.2K	﹤0.01%	1307
2021 Q2	–	Sell	-4	Closed	-$111K	–	1625
2021 Q1	$111K	Buy	+4	New	+$147K	0.01%	689
2020 Q2	–	Sell	-2	Closed	-$55K	–	1573
2020 Q1	$55K	Buy	+2	New	+$68.1K	﹤0.01%	1182
2019 Q4	–	Hold	0	–	–	–	2271
2019 Q1	–	Hold	0	–	-$21K	–	2202
2018 Q4	–	Hold	0	–	–	–	1974
2018 Q3	–	Hold	0	–	-$24K	–	2842
2018 Q2	–	Hold	0	–	–	–	2554
2018 Q1	–	Hold	0	–	-$21K	–	2839
2017 Q4	–	Hold	0	–	–	–	1625
2017 Q3	–	Sell	-2	Closed	-$144K	–	1100
2017 Q2	$144K	Buy	2 +1	+100%	+$43.5K	0.03%	613
2017 Q1	$28K	Buy	+1	New	+$70K	0.01%	832

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

P.J. Schmidt Investment Management (PJS) Cedarburg, Wisconsin $643M AUM 21.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return

Two Sigma Securities's MBRX Position: Q3 2023 in Review

Two Sigma Securities sold out of Moleculin Biotech (MBRX) in Q3 2023, closing a stake of 2 shares — an estimated $7.59K sold.

Two Sigma Securities first reported a position in MBRX in Q1 2017 and held it in 7 quarters. The position peaked at $144K in Q2 2017. 13 funds tracked by Wall St. Rank hold MBRX as of Q3 2023.

Two Sigma Securities reported no remaining Moleculin Biotech position as of Q3 2023 after selling out during the quarter.
Two Sigma Securities sold 2 Moleculin Biotech shares in Q3 2023, an estimated $7.59K.
Two Sigma Securities first reported a position in Moleculin Biotech in Q1 2017 and held it in 7 quarters.
Two Sigma Securities's Moleculin Biotech position peaked at $144K in Q2 2017.
13 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2023.

Based on Two Sigma Securities's 13F filing for Q3 2023, filed 14 Nov 2023.